Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
Unknown status
University of South Florida
Phase 4
2014-09-01
The purpose of this study is to see if selegiline and tadalafil (generic for Cialis®) results
in an improvement in Erectile dysfunction (ED) in male patients with Parkinson's disease (PD)
and moderate ED. Male PD patients who have an incomplete response to tadalafil alone will be
given both medications to see if the addition of selegiline improves ED symptoms more than
tadalafil alone. It is common practice for a medical doctor to prescribe these two drugs to a
patient like you. However, there have been no studies conducted to examine the effects of
these medications when taken together.
Selegiline is normally prescribed for PD patients that are taking carbidopa/levodopa who are
not receiving complete benefit from carbidopa/levodopa.
Tadalafil is normally prescribed to men who have erectile dysfunction and/or benign prostatic
hyperplasia (BPH).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
